The New Board Members Will Bring Industry
Experience to Contribute to Company Growth
WOODINVILLE, Wash., Nov. 2, 2022
/PRNewswire/ -- Anavasi Diagnostics ('Anavasi'), an NIH/RADx
medical technology company focused on the development of novel
molecular diagnostic testing, recently announced the election of
three new outside members to its Board of Directors, Bryan Crane, PhD, Arthur
Kirsch, and David Vied.
"We are thankful to have these three talented individuals join
the board," said Nelson
Patterson, President, and CEO of Anavasi Diagnostics. "They
all bring valuable personal perspectives and professional
experience to the Board that will greatly contribute to the growth
of Anavasi as we complete our clinical trials, broaden our product
development and portfolio, and work towards commercialization."
Bryan Crane, Ph.D. is
currently the Vice President, Head of System Design at Illumina
(NSDQ: ILMN), a global leader in the field of instrumentation for
genomic analysis. Dr. Crane has served in R&D at Illumina for
15 years and has been deeply involved in the innovation and
productization of several generations of market-leading
instrumentation and consumable platforms. Dr. Crane is responsible
for collaborative optimization of product architecture,
prioritizing R&D investment, evolving the development process,
and maintaining partnerships with worldwide suppliers. He is also
responsible for growing and developing a large engineering team,
instilling the innovative, fast-moving R&D culture of
Illumina.
Arthur Kirsch is
currently a director of Liquidia Corp. (Nasdaq: LQDA) a
biopharmaceutical company focused on the development and
commercialization of products for pulmonary hypertension. He has
served on several public company boards, typically as an audit
committee member. Arthur had a 40+ year career (Drexel Burnham, Vector Securities, GCA Global)
in investment banking working with a variety of companies, from
start-ups to large public entities. He specialized in healthcare,
advising companies on everything from capital raising to strategic
transactions.
David L. Vied is the Global Sector Leader for the
Medical Devices practice for Korn
Ferry. He additionally serves as a director of Cyanotech
Corporation (Nasdaq: CYAN), a developer and marketer of microalgae
based nutritional supplements. For over 25 years, David has advised
medical device clients on talent management and talent assessment
issues, addressing such topics as CEO succession, innovation and
transformation acceleration, and executive development. He has
conducted search assignments in areas that range from medical
affairs, research and development, and regulatory compliance
through to CEO and board roles. His clients run the gamut of the
industry, from pre-revenue start-up to established and dominant
multi-billion-dollar market cap environments.
Mr. Crane, Mr. Kirsch, and Mr. Vied join a seasoned executive
team of Board of Directors, led by the President and CEO,
Nelson Patterson. During his career,
Mr. Patterson has moved between international conglomerates
(Procter & Gamble, Baxter International) to early-launch,
high-growth startups (SonoSite, Aerogen, HealthySole). While at
Baxter, Patterson oversaw the purchase and integration of SIGMA
Medical devices into the Baxter Infusion Systems portfolio and ran
the BioPharma Solutions (BPS) contract drug manufacturing business
unit as General Manager. His background also includes extensive new
product design and development, production, fundraising, sales, and
marketing.
The remaining Board of Directors are:
- Barry Lutz, Ph.D. – Co-Founder
and Chief Scientific Officer
- Bob Atkinson – Co-Founder and
Chief of Innovation and Technology
- Minh Duong – Co-Founder and
Chief Engineer
- Pat Atkinson – Controller and
Investor
- Debra Patterson, Ph.D. – Vice
President of Regulatory Affairs and Investor
To date, Anavasi has completed a $6.0 million Seed
Round (convertible note), a $2.6 million Founder's Round,
and is currently raising funds in a previously announced
$20M Series A round. In November
2021, the company was awarded $14.9 million from the
National Institutes of Health (NIH) Rapid Acceleration of
Diagnostics (RADx) initiative to accelerate the launch and broad
market availability of the AscencioDx™ molecular diagnostic
platform for the detection of RNA indicative of the SARS-CoV-2 /
COVID-19 virus.
About Anavasi
Diagnostics
Anavasi Diagnostics is a rapidly growing medical technology
company focused on developing novel molecular diagnostic testing
using a proprietary reverse transcriptase methodology
(patent-pending). As a spin-out of the University of
Washington, Anavasi's technology
platform was developed by renowned researchers in UW's
bioengineering department. The Company's quest to successfully
commercialize this technology is led by top medical device and
clinical diagnostics executives, manufacturing experts and a former
Microsoft software veteran. The team's combined experience has been
responsible for the introduction of more than forty
medical/diagnostic products and hundreds of peer-reviewed research
publications. More information can be obtained
at https://anavasidx.com.
Follow Anavasi Diagnostics on:
Linked In: https://www.linkedin.com/company/anavasidx/
Facebook: https://www.facebook.com/AnavasiDx
Instagram: https://www.instagram.com/anavasidx/
Twitter: https://twitter.com/AnavasiDx
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anavasi-diagnostics-announces-newly-elected-outside-board-of-directors-301666063.html
SOURCE Anavasi Diagnostics